Company news
Calidi Biotherapeutics, Inc. (AMEX:CLDI) news
Calidi Biotherapeutics, Inc. news releases on 6ix. Latest, Sep 17, 2026: Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
Press releases & updates
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
September 17, 2026
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
July 22, 2026
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
July 20, 2026
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
June 24, 2026
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
June 16, 2026
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
June 8, 2026
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
May 26, 2026
Calidi Biotherapeutics Provides Required NYSE American Disclosure
May 22, 2026
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
May 14, 2026
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
April 29, 2026
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
April 21, 2026
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
April 20, 2026
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
April 15, 2026
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
April 14, 2026
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
April 7, 2026
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
April 2, 2026
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
April 1, 2026
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
March 27, 2026
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
March 24, 2026
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
March 12, 2026
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
March 8, 2026
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
March 6, 2026
Calidi Biotherapeutics Announces Proposed Public Offering
March 5, 2026
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
February 20, 2026
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
February 12, 2026
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
January 28, 2026
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
November 17, 2025
Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
November 13, 2025
Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC
November 10, 2025
Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
November 4, 2025
Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND
November 3, 2025
Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting
October 30, 2025
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
October 22, 2025
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
September 29, 2025
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
August 21, 2025
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
August 20, 2025
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
August 8, 2025
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
July 29, 2025
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
July 25, 2025
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24
July 22, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
July 10, 2025
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
July 9, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
July 8, 2025
Calidi Biotherapeutics Announces Shareholder Letter from CEO
June 27, 2025
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting
June 2, 2025
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
May 14, 2025
Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting
April 28, 2025